Leadership

Mylan N.V. is a publicly traded company on the NASDAQ Global Select Market and incorporated under the laws of the Netherlands, as set forth in its Articles of Association. 

The Chief Executive Officer and other executive officers of Mylan N.V. carry out the day-to-day conduct of Mylan N.V.'s worldwide businesses at the company's principal offices in Canonsburg, Pennsylvania. Duties and standards of conduct for Mylan employees, officers and directors are set forth in the company’s Code of Business Conduct and Ethics, as well as in the Code of Ethics for the Chief Executive Officer, Chief Financial Officer and Corporate Controller. 

Mylan N.V. is managed and controlled under the oversight of the company's board of directors in the United Kingdom, where the board generally meets. The board has established seven committees, each of which operates pursuant to a written charter. Each director is elected annually by the company’s shareholders. Certain of the directors’ duties, rights and responsibilities are detailed in the company’s Articles of Association, Board Rules, and Corporate Governance Principles.



Board of Directors

  • Heather Bresch

    Chief Executive Officer
    Mylan


    Executive Director

    Heather Bresch is chief executive officer of Mylan, one of the world’s leading pharmaceutical companies. She also serves on the company’s board of directors. As CEO, she is responsible for a workforce of more than 35,000, a powerful global research and development platform, a manufacturing footprint comprising more than 50 facilities, and a portfolio of more than 7,500 generic and branded pharmaceuticals sold in more than 165 countries and territories. 

    Career at Mylan

    Throughout her 25-year career with Mylan, Bresch, who started with the company as a data-entry clerk, has held roles of increasing responsibility in more than 15 functional areas. Prior to becoming CEO, Bresch served as Mylan’s president, where she was responsible for the day-to-day operations of the company. Before that, she served as Mylan’s chief operating officer and chief integration officer, leading the successful integration of two international acquisitions – Matrix Laboratories and Merck KGaA’s generics business – which more than doubled the size of the company and transformed Mylan from a purely U.S. company to a global one.

    Leading the Next Chapter of Mylan’s Growth and Performance

    As CEO, Bresch is leading the next chapter of Mylan’s growth and performance, and further differentiating the company from its competitors by transforming it from a pharmaceutical company into a healthcare company. This strategy includes plans to double the size of Mylan’s product portfolio, manufacturing capacity and adjusted earnings between 2012 and 2018, enhance its technologies and capabilities, expand its reach across geographies and commercial channels, and develop new services that further enhance Mylan’s relationship with customers and patients.

    In executing on this strategy and continuing to satisfy unmet needs, Mylan is developing and launching hundreds of new generic, specialty and over-the-counter products annually. Additionally, Mylan has continued to serve as a leading consolidator in the industry, with recent transactions including Abbott’s non-U.S. developed markets specialty and branded generics business and Meda, a leading international specialty pharmaceutical company that sells both prescription and over-the-counter products. Mylan also continues to focus on complex and difficult-to-manufacture products and is developing portfolios of complex products including biosimilars, insulin analog and respiratory products.

    To achieve Mylan’s goals, Bresch emphasizes a collaborative company culture focused on leading, learning, teaching and performing to inspire innovation and help set new standards in healthcare.

    Providing Passionate Global Leadership on Key Issues

    Mylan’s mission is to provide the world’s 7 billion people access to high quality medicine and to “do good while doing well.” Over the course of her career at the company, Bresch has been a champion of initiatives and policy changes aimed at removing barriers that hinder access.

    Among her policy priorities is ensuring that everyone living with HIV/AIDS has access to high quality, affordable drugs and advocating for treatment soon after diagnosis to produce better health outcomes, reduce HIV transmission and create long-term cost savings. Approximately 50% percent of patients being treated for HIV/AIDS in the developing world today rely on a Mylan product.

    Bresch also has been a leading advocate for global competitiveness and global quality standards. For instance, driven by Mylan’s unmatched commitment to quality, Bresch was instrumental in the development of the Generic Drug User Fee Act (GDUFA) which aims to hold all drugs sold in the U.S. to one quality standard. In addition, she advocated for changes to the Federal Food, Drug and Cosmetic Act of 1938 to arm the U.S. Food and Drug Administration (FDA) with the resources and authority needed to regularly inspect U.S. and foreign plants at the same rate. Both of these provisions were included in the Food and Drug Administration Safety and Innovation Act (FDASIA), landmark legislation that was signed into law in July 2012.

    Moreover, Bresch is actively advocating for the implementation of a viable abbreviated approval pathway for safe and effective generic versions of biologic drugs, which will provide patients with access to lower-cost versions of these life-saving products. In addition, Bresch is passionate about increasing awareness of and preparedness for life-threatening allergic reactions, called anaphylaxis, and has advocated for measures that provide people immediate access to Epinephrine auto-injectors, as the drug is considered the first-line treatment for anaphylaxis.

    Earlier in her career, Bresch played a vital role in the passage of the 2003 Medicare Modernization Act, a congressional revision to the Hatch-Waxman Act of 1984, which helped to ensure consumer access to affordable pharmaceuticals.

    Bresch served as chair of the Generic Pharmaceutical Association’s board of directors in 2016, 2005, and 2004, and as vice chair in 2003 and 2006. She is a frequent speaker on issues such as affordable healthcare and global competitiveness, and has testified before the U.S. Congress and FDA on issues related to access to medicine. Heather is the pharmaceutical industry’s first female CEO of a Fortune 500 company, and has been named by Fortune magazine as one of its “50 Most Powerful Women.”

    Bresch earned her undergraduate degree from West Virginia University.

  • Wendy Cameron*

    Director and Co-owner
    Cam Land LLC


    Non-Executive Director

    Wendy Cameron was appointed to Mylan’s board of directors in 2002 and was among the directors who helped guide Mylan during the company’s period of global transformation. She serves as Chair of the Compensation Committee.

    Cameron and other members of her family were owners of Cameron Coca-Cola Bottling Company, one the largest bottling companies in the U.S. By the late 1990s, Cameron Coca-Cola was the 10th-largest Coke bottler and the second-longest-running family-owned Coke bottler in the nation. In 1998, the company was purchased by Coca-Cola Enterprises, the largest Coke bottling company in the world. From 1981 to 1998, she also served the company as vice president of divisional sales and governmental affairs.

    Cameron is now a director and co-owner of Cam Land, a harness racing business in Washington, Pa. Previously, Cameron also had served as chairman of the board of trustees for Washington Hospital and chairman of the Washington Hospital executive committee. She had been a member of the hospital’s board of trustees for 15 years.

    Cameron earned a Bachelor of Science degree in business management and a Bachelor of Science degree in equine science from Otterbein University in Westerville, Ohio.

    *Independent Director

  • Robert J. Cindrich*

    President
    Cindrich Consulting


    Non-Executive Director

    Robert Cindrich was appointed to the board of directors of Mylan in March 2011. He is a member of Mylan's Compliance, Governance and Nominating and Science and Technology Committees.

    Cindrich is a distinguished attorney and former jurist who is currently the President of Cindrich Consulting. Previously, Cindrich served as senior advisor to the Office of the President at the University of Pittsburgh Medical Center (UPMC), a global health enterprise. In that role, Cindrich advises UPMC's senior management and board of directors on key corporate governance and strategic business issues. He also is jointly responsible for UPMC's biosecurity initiatives.

    Cindrich previously was senior vice president and chief legal officer for UPMC. Before joining UPMC, Cindrich served as a highly respected judge in the U.S. District Court for Western Pennsylvania for 10 years. Prior to that appointment, he was active in both government and private practice, including positions as the Allegheny County assistant public defender and assistant district attorney and U.S. attorney for the Western District of Pennsylvania.

    Cindrich also has served as an adjunct professor at the University of Pittsburgh School of Law and at the Duquesne University School of Law. In addition, he is chair of the University of Pittsburgh School of Law's board of visitors, chair of the Heinz History Center, chair of the 21st Century Biodefense Inc. board of directors and a member of the board of directors of UPMC Mercy Hospital. Cindrich also serves on the board of directors and audit committee of Allscripts Healthcare Solutions Inc.

    He has belonged to numerous professional organizations, including the American Bar Association, the American Bar Foundation, the Pennsylvania Bar Association, the Allegheny County Bar Association, the American College of Trial Lawyers and the Academy of Trial Lawyers of Allegheny County.

    His awards and honors include Jaycee Man of the Year in Law and Government, the Variety Club Pride of Pittsburgh Award, the Joseph F. Weis, Jr. Distinguished Service Award, the Wittenberg University Distinguished Alumni Award and the University of Pittsburgh Legacy Laureate Award.

    Cindrich is a graduate of the University of Pittsburgh School of Law. He also served in the U.S. Army Reserves and the U.S. Air Force Reserves.


    *Independent Director

  • Robert J. Coury

    Chairman
    Mylan
     
    Non-Executive Director

    Robert J. Coury is the Chairman of Mylan N.V.  Under his visionary leadership, Mylan has transformed from the third largest generics pharmaceutical company in the U.S. into one of the largest pharmaceutical companies in the world, earning spots in both the S&P 500 and, prior to the company’s reincorporation outside of the U.S. in 2015, the Fortune 500. 

    Mr. Coury was first elected to Mylan’s board of directors in February 2002, having served since 1995 as a strategic advisor to the company.  He became the board’s vice chairman shortly after his election and served as CEO from September 2002 until January 2012, and as executive chairman from 2012 until he became chairman in June 2016.

    Since 2007, Mr. Coury has led the company through a series of transactions totaling more than $25 billion, which transformed Mylan into a global powerhouse within the highly competitive pharmaceutical industry, with more than 35,000 employees and products sold in over 165 countries.  

    In 2007, Mylan purchased India-based Matrix Laboratories, a major producer of active pharmaceutical ingredients, and the generics business of Europe-based Merck KGaA.  Subsequent acquisitions under Mr. Coury’s leadership further expanded the company into new therapeutic categories and greatly enhanced its geographic and commercial footprint.  In 2010, Mylan acquired Bioniche Pharma, a global injectables business in Ireland; in 2012, Mylan acquired India-based Agila Specialties, a global injectables company; and in 2015, Mylan acquired Abbott Laboratories’ non-U.S. developed markets specialty and branded generics business, and Famy Care’s women’s healthcare businesses.  Most recently, Mylan acquired Meda, a leading international specialty pharmaceutical company that sells both prescription and over-the-counter products.   

    During this period of expansion, the company built an unmatched, high quality foundation for the future supporting Mylan’s mission of providing the world’s 7 billion people with access to high quality medicine, and benefiting patients, customers, investors, and other stakeholders. 

    Before becoming executive chairman in 2012, Mr. Coury also executed a successful executive leadership transition after cultivating and developing a powerful leadership team.  Grooming executive talent from within and recruiting dynamic leaders from outside the company were both key components of the company’s past, current and future growth strategies. 

    Prior to joining Mylan, Mr. Coury was the principal of Coury Consulting, a boutique business advisory firm he formed in 1989, and The Coury Financial Group, a successful financial and estate planning firm, which he founded in 1984. 

    Mr. Coury is also the founder and president of the Robert J. Coury Family Foundation, which is a charitable organization formed to help support his philanthropic efforts and his mission of giving back. He has served as a member of the University of Southern California President's Leadership Council since 2014. 

    Mr. Coury earned a Bachelor of Science degree in industrial engineering from the University of Pittsburgh.              


  • JoEllen Lyons Dillon*

    Executive Vice-President,
    Chief Legal Officer and
    Corporate Secretary
    The ExOne Company

    Non-Executive Director

    JoEllen Lyons Dillon was elected to the board of directors of Mylan in 2014. She currently chairs Mylan's Governance and Nominating Committee and is a member of its Audit, Compensation and Executive Committees.

    Ms. Dillon has served as Chief Legal Officer and Corporate Secretary of The ExOne Company (NASDAQ: XONE), a global provider of three-dimensional printing machines, since March 2013, and has served as Executive Vice President since December 2014. 

    Previously, she was a legal consultant on ExOne’s initial public offering. Prior to that experience, Ms. Dillon was a partner with Reed Smith LLP, a law firm, from 2002 until 2011. She had previously been at the law firm Buchanan Ingersoll & Rooney PC from 1988 until 2002, where she became a partner in 1997. Ms. Dillon is the former Chair, and currently serves as the Audit Committee Chair of, the Allegheny District chapter of the National Multiple Sclerosis Society. This experience, as well as her substantial legal and leadership experience, and judgment, led the Board to nominate her as a Director.


    *Independent Director

  • Neil Dimick*

    Retired Executive Vice President
    and Chief Financial Officer
    AmerisourceBergen Corporation


    Non-Executive Director

    Neil Dimick was elected to the Mylan board of directors in October 2005. He chairs Mylan's Audit Committee and is a member of the Executive and Finance Committees.

    Dimick served as executive vice president and chief financial officer of AmerisourceBergen Corporation from 2001 to 2002, before which he was senior executive vice president and chief financial officer of Bergen Brunswig Corporation from 1992 to 2001.

    Dimick also serves on the boards of Alliance Imaging Inc., Resources Connection Inc., Thoratec Corporation and WebMD Corporation.


    *Independent Director

  • Melina Higgins*

    Former Partner
    Goldman Sachs


    Non-Executive Director

    Melina Higgins was elected to the board of directors of Mylan in 2013. She currently chairs Mylan's Finance Committee and is a member of its Audit and Compensation Committees.

    Melina Higgins is an experienced financier, having served as a partner and in other senior roles at Goldman Sachs during her nearly 20 year career at the firm. Higgins joined Goldman Sachs in 1989 and retired from the firm in January 2010. During her tenure at Goldman Sachs, Higgins served as a member of the Investment Committee of the Principal Investment Area, which oversaw and approved global private equity and private debt investments and was one of the largest alternative asset managers in the world. She also served as head of the Americas as well as co-chairperson of the Investment Advisory Committee for the GS Mezzanine Partners funds, which managed over $30 billion of assets and was the global leader in its industry.

    Higgins has significant board experience, having served as a director for numerous companies across a wide range of industries. Higgins serves on the Women’s Leadership Board of Harvard University’s John F. Kennedy School of Government, and U.S. Banker ranked Higgins as one of the Top 20 Nonbank Women in Finance. She holds an M.B.A. from Harvard Business School and a B.A. from Colgate University.


    *Independent Director



  • Rajiv Malik

    President
    Mylan


    Executive Director

    Rajiv Malik is president of Mylan and also serves on the company’s board of directors. He leads all global commercial and operational activities for the company, including sales and marketing in more than 165 countries and territories and operations that manage a portfolio of more than 7,500 marketed  products, a pipeline of approximately 1,200 products and 50 manufacturing facilities around the world. Mylan has a manufacturing capacity of more than 80 billion doses annually with capabilities that include oral solid doses, injectables, complex products including respiratory and biologics, and active pharmaceutical ingredients (API). The functions managing these diverse capabilities include quality, R&D, regulatory, medical affairs, manufacturing, supply chain and sourcing. 

    Malik is also responsible for the commercial and operational execution of Mylan’s growth areas, including the company’s antiretroviral (ARV)/infectious disease, biologics, dermatology, injectables, insulin analog, over-the-counter and respiratory platforms. Malik oversees business development, integration of acquired businesses and information technology with a focus on expanding and enhancing Mylan’s portfolio, product technologies and commercial capabilities.  

    Malik actively promotes the importance and necessity of quality within the company and industry. With a patient-first mentality and a personal philosophy that quality is everyone’s responsibility, Malik has enhanced a long-standing commitment to and obsession with high quality standards that permeate Mylan’s unconventional corporate culture and workforce of about 35,000.  

    Prior to his current role as president, Malik held other leadership positions at Mylan since January 2007, which is when Mylan acquired a controlling stake in Matrix Laboratories Limited (now Mylan Laboratories Limited), one of the world's largest suppliers of API and producers of generic finished dose ARVs used to treat HIV/AIDS, primarily for developing markets. Malik was Matrix’s CEO, and during his tenure there, he established the company as a key ARV supplier in developing markets through relationships with Gilead, the Clinton Health Access Initiative (CHAI) and the Global Fund to Fight AIDS, Tuberculosis and Malaria. After Mylan acquired Matrix, Malik focused on novel ARV finished doses, which today form the backbone of Mylan’s leading ARV franchise.  

    Among early contributions at Mylan, Malik partnered with current CEO Heather Bresch to lead integration efforts among Mylan, Matrix and the generics business of Merck KGaA, another 2007 acquisition that catapulted Mylan onto the global stage. Simultaneously, Malik led the creation of a globalized operating platform with a supply chain and manufacturing network that could support the size and complexity of serving all markets around the world. His work also focused on significantly expanding and diversifying the company’s global product portfolio, pipeline and manufacturing footprint. Malik continued to play a key role and further expand the company’s operating footprint through the acquisition of Bioniche Pharma and Agila Specialties, two of the world’s most preeminent makers of injectables products. Most recently, Malik played a pivotal role to acquire and close on the acquisition of Abbott’s Established Products business in non-U.S. developed markets, including Europe, Australia, Japan and Canada.  Malik also played a pivotal role in the acquisitions and integrations of Renaissance and Meda which further diversified Mylan’s commercial and operations platform in dermatology and OTC.

    Malik has approximately 30 years of experience in the global pharmaceutical industry. Prior to joining Matrix in 2005, Malik was head of Global Development and Regulatory at Sandoz. He started in R&D at Ranbaxy Laboratories, rising to head of Generics R&D. Malik earned his master's degree in pharmaceutical technology from Punjab University, India, and has more than 60 process patents to his credit.

  • Mark W. Parrish*

    Chairman and CEO
    Trident USA Health Services


    Non-Executive Director

    Mark W. Parrish was elected to the board of directors of Mylan in 2009, and currently serves as the Lead Independent Director and Vice Chairman of the board. He chairs Mylan's Compliance Committee and is a member of its Audit and Executive Committees.

    Parrish is the chairman and chief executive officer (CEO) of Trident USA Health Services, the nation's largest provider of mobile X-ray and laboratory services to the long-term care industry. He also is president of the International Federation of Pharmaceutical Wholesalers, an association comprising the largest pharmaceutical wholesalers and pharmaceutical supply chain service companies in the world. He also serves as a senior advisor to Frazier Healthcare Ventures, a healthcare-oriented growth equity firm.

    Previously, Parrish was CEO of health care supply chain services for Cardinal Health, a $91 billion global manufacturer and distributor of medical and surgical supplies and technologies. Parrish also held a variety of other leadership roles at Cardinal Health, including group president of pharmaceutical supply chain services, president and chief operating officer of pharmaceutical supply chain services, chairman and CEO of pharmaceutical distribution and provider services, executive vice president and group president of pharmaceutical distribution and president of Medicine Shoppe.

    Prior to joining Cardinal Health, Parrish held positions in health care distribution companies in the pharmaceutical and medical/surgical products sectors.

    Parrish earned a Bachelor of Arts degree from the University of California, Berkeley.

    *Independent Director

  • Randall L. Vanderveen, Ph.D.*

    Professor
    Senior Advisor, USC Leonard D. Schaeffer Center for Health Policy & Economics
    Special Assistant to the Dean for Development
    Director, Biles Leadership Center


    Non-Executive Director

    Randall “Pete” Vanderveen, Ph.D., was elected to the board of directors of Mylan in 2002. He is a member of the Compliance Committee and serves as Chair of the Science and Technology Committee.

    Dr. Vanderveen is currently Professor of Pharmaceutical Policy and Economics, Senior Adviser to the Leonard D. Schaeffer Center of Heath Policy and Economics, Director of the Margaret and John Biles Center for Leadership, and Senior Adviser to the Dean for Advancement at the School of Pharmacy, University of Southern California in Los Angeles, California. Vanderveen previously served as Dean, Professor and John Stauffer Decanal Chair of the University of Southern California School of Pharmacy from 2005-2015 where he was named “Outstanding Pharmacy Dean in the Nation” in 2013 by the American Pharmacist Association. During Dr. Vanderveen’s tenure as Dean, the School of Pharmacy rose from a U.S. News and World Report ranking of 19th to the 9th in the country among the over 160 Pharmacy Schools in the nation. From 1998 until 2005, he was Dean and Professor of Pharmacy of the School of Pharmacy and the Graduate School of Pharmaceutical Sciences at Duquesne University in Pittsburgh. Previously, he served in a variety of academic positions at Oregon State University/Oregon Health Sciences University and Ferris State University.

    Vanderveen has practiced pharmacy in independent community pharmacies, chain drug stores, nursing home settings and hospital pharmacies. Vanderveen has served as consultant and advisor to McKesson, Rite Aid, Eckerd, Walgreens, Bristol-Myers Squibb, Upjohn, Merck and Pfizer.

    Vanderveen has also served as a consultant to the Oregon Medical Assistance Program, the Michigan Department of Mental Health, Providence Medical Center, the Veterans Administration Hospital and the Oregon Health Sciences Hospital in Portland, Ore.

    Vanderveen was honored as a "Fellow" in both the American Pharmacists Association and the American Society of Health-Systems Pharmacists (ASHP). He is a member and former board of directors member of the American Association of Colleges of Pharmacy and a member of the board of directors of the National Institute on Pharmaceutical Technology and Education (NIPTE). He also served on the commission on credentialing for the ASHP. He was selected as "Pharmacist of the Year" by the Michigan Pharmacists Association and has been honored by his alma mater, Purdue University, with a Distinguished Alumnus Award and the Glen A. Sperandio Award for achievement in pharmacy. He is currently a member of the education advisory committee for the National Association of Chain Drug Stores. Vanderveen is a member of the American Association of Pharmaceutical Scientists, the American Society of Consultant Pharmacists, the American College of Clinical Pharmacy, the Academy of Managed Care Pharmacists, the College of Psychiatric and Neurologic Pharmacists and the National Community Pharmacists Association. Vanderveen has published referred articles and book chapters on pharmacokinetics, innovative educational strategies and leadership in nationally recognized journals and has published op-eds in the Wall Street Journal and Politico on issues of improving healthcare delivery.

    Vanderveen received a Bachelor of Science degree in pharmacy and a master of science degree in clinical pharmacy from Purdue University. He completed an ASHP-accredited residency at Bronson Medical Center in Kalamazoo, Mich. Vanderveen received his Ph.D. in university administration from Michigan State University.


    *Independent Director

  • Sjoerd S. Vollebregt*

    Chairman of the Supervisory Board of Heijmans N.V.


    Non-Executive Director

    Sjoerd S. Vollebregt was elected to the board of directors of Mylan in 2017. He is a member of its Compliance, Finance and Governance and Nominating Committees.

    Mr. Vollebregt has been Chairman of the Supervisory Board of Heijmans N.V., a Euronext Amsterdam listed company that operates in property development, residential building, non-residential building, roads, and civil engineering, since 2015, and Chairman of the Advisory Board of Airbus Defence and Space Netherlands B.V., a subsidiary of Airbus SE, a Euronext Paris listed company, that develops solar arrays, satellite instruments, and structures for launchers, since 2015. Mr. Vollebregt had served as Chairman of the Executive Board of Stork B.V. and its predecessor from 2002 to 2014, which was an Amsterdam Stock Exchange listed industrial group until 2008, consisting of a global provider of knowledge-based maintenance, modification, and asset integrity products and services, food and textile equipment manufacturer, and Chief Executive Officer of Fokker Technologies Group B.V., an aerospace company and a Stork B.V. subsidiary from 2010 to 2014. Previously, Mr. Vollebregt served as a member of the Supervisory Board of TNT Express N.V., an international courier delivery services company, from 2013 to 2016 and has held various other senior positions at Excel plc, Ocean plc, Intexo Holding, and Royal Van Ommeren.

     

    *Independent Director

Executive Management

  • Heather Bresch

    Chief Executive Officer
    Mylan


    Executive Director

    Heather Bresch is chief executive officer of Mylan, one of the world’s leading pharmaceutical companies. She also serves on the company’s board of directors. As CEO, she is responsible for a workforce of more than 35,000, a powerful global research and development platform, a manufacturing footprint comprising more than 50 facilities, and a portfolio of more than 7,500 generic and branded pharmaceuticals sold in more than 165 countries and territories. 

    Career at Mylan

    Throughout her 25-year career with Mylan, Bresch, who started with the company as a data-entry clerk, has held roles of increasing responsibility in more than 15 functional areas. Prior to becoming CEO, Bresch served as Mylan’s president, where she was responsible for the day-to-day operations of the company. Before that, she served as Mylan’s chief operating officer and chief integration officer, leading the successful integration of two international acquisitions – Matrix Laboratories and Merck KGaA’s generics business – which more than doubled the size of the company and transformed Mylan from a purely U.S. company to a global one.

    Leading the Next Chapter of Mylan’s Growth and Performance

    As CEO, Bresch is leading the next chapter of Mylan’s growth and performance, and further differentiating the company from its competitors by transforming it from a pharmaceutical company into a healthcare company. This strategy includes plans to double the size of Mylan’s product portfolio, manufacturing capacity and adjusted earnings between 2012 and 2018, enhance its technologies and capabilities, expand its reach across geographies and commercial channels, and develop new services that further enhance Mylan’s relationship with customers and patients.

    In executing on this strategy and continuing to satisfy unmet needs, Mylan is developing and launching hundreds of new generic, specialty and over-the-counter products annually. Additionally, Mylan has continued to serve as a leading consolidator in the industry, with recent transactions including Abbott’s non-U.S. developed markets specialty and branded generics business and Meda, a leading international specialty pharmaceutical company that sells both prescription and over-the-counter products. Mylan also continues to focus on complex and difficult-to-manufacture products and is developing portfolios of complex products including biosimilars, insulin analog and respiratory products.

    To achieve Mylan’s goals, Bresch emphasizes a collaborative company culture focused on leading, learning, teaching and performing to inspire innovation and help set new standards in healthcare.

    Providing Passionate Global Leadership on Key Issues

    Mylan’s mission is to provide the world’s 7 billion people access to high quality medicine and to “do good while doing well.” Over the course of her career at the company, Bresch has been a champion of initiatives and policy changes aimed at removing barriers that hinder access.

    Among her policy priorities is ensuring that everyone living with HIV/AIDS has access to high quality, affordable drugs and advocating for treatment soon after diagnosis to produce better health outcomes, reduce HIV transmission and create long-term cost savings. Approximately 50% percent of patients being treated for HIV/AIDS in the developing world today rely on a Mylan product.

    Bresch also has been a leading advocate for global competitiveness and global quality standards. For instance, driven by Mylan’s unmatched commitment to quality, Bresch was instrumental in the development of the Generic Drug User Fee Act (GDUFA) which aims to hold all drugs sold in the U.S. to one quality standard. In addition, she advocated for changes to the Federal Food, Drug and Cosmetic Act of 1938 to arm the U.S. Food and Drug Administration (FDA) with the resources and authority needed to regularly inspect U.S. and foreign plants at the same rate. Both of these provisions were included in the Food and Drug Administration Safety and Innovation Act (FDASIA), landmark legislation that was signed into law in July 2012.

    Moreover, Bresch is actively advocating for the implementation of a viable abbreviated approval pathway for safe and effective generic versions of biologic drugs, which will provide patients with access to lower-cost versions of these life-saving products. In addition, Bresch is passionate about increasing awareness of and preparedness for life-threatening allergic reactions, called anaphylaxis, and has advocated for measures that provide people immediate access to Epinephrine auto-injectors, as the drug is considered the first-line treatment for anaphylaxis.

    Earlier in her career, Bresch played a vital role in the passage of the 2003 Medicare Modernization Act, a congressional revision to the Hatch-Waxman Act of 1984, which helped to ensure consumer access to affordable pharmaceuticals.

    Bresch served as chair of the Generic Pharmaceutical Association’s board of directors in 2016, 2005, and 2004, and as vice chair in 2003 and 2006. She is a frequent speaker on issues such as affordable healthcare and global competitiveness, and has testified before the U.S. Congress and FDA on issues related to access to medicine. Heather is the pharmaceutical industry’s first female CEO of a Fortune 500 company, and has been named by Fortune magazine as one of its “50 Most Powerful Women.”

    Bresch earned her undergraduate degree from West Virginia University.

  • Rajiv Malik

    President
    Mylan


    Executive Director

    Rajiv Malik is president of Mylan and also serves on the company’s board of directors. He leads all global commercial and operational activities for the company, including sales and marketing in more than 165 countries and territories and operations that manage a portfolio of more than 7,500 marketed  products, a pipeline of approximately 1,200 products and 50 manufacturing facilities around the world. Mylan has a manufacturing capacity of more than 80 billion doses annually with capabilities that include oral solid doses, injectables, complex products including respiratory and biologics, and active pharmaceutical ingredients (API). The functions managing these diverse capabilities include quality, R&D, regulatory, medical affairs, manufacturing, supply chain and sourcing. 

    Malik is also responsible for the commercial and operational execution of Mylan’s growth areas, including the company’s antiretroviral (ARV)/infectious disease, biologics, dermatology, injectables, insulin analog, over-the-counter and respiratory platforms. Malik oversees business development, integration of acquired businesses and information technology with a focus on expanding and enhancing Mylan’s portfolio, product technologies and commercial capabilities.  

    Malik actively promotes the importance and necessity of quality within the company and industry. With a patient-first mentality and a personal philosophy that quality is everyone’s responsibility, Malik has enhanced a long-standing commitment to and obsession with high quality standards that permeate Mylan’s unconventional corporate culture and workforce of about 35,000.  

    Prior to his current role as president, Malik held other leadership positions at Mylan since January 2007, which is when Mylan acquired a controlling stake in Matrix Laboratories Limited (now Mylan Laboratories Limited), one of the world's largest suppliers of API and producers of generic finished dose ARVs used to treat HIV/AIDS, primarily for developing markets. Malik was Matrix’s CEO, and during his tenure there, he established the company as a key ARV supplier in developing markets through relationships with Gilead, the Clinton Health Access Initiative (CHAI) and the Global Fund to Fight AIDS, Tuberculosis and Malaria. After Mylan acquired Matrix, Malik focused on novel ARV finished doses, which today form the backbone of Mylan’s leading ARV franchise.  

    Among early contributions at Mylan, Malik partnered with current CEO Heather Bresch to lead integration efforts among Mylan, Matrix and the generics business of Merck KGaA, another 2007 acquisition that catapulted Mylan onto the global stage. Simultaneously, Malik led the creation of a globalized operating platform with a supply chain and manufacturing network that could support the size and complexity of serving all markets around the world. His work also focused on significantly expanding and diversifying the company’s global product portfolio, pipeline and manufacturing footprint. Malik continued to play a key role and further expand the company’s operating footprint through the acquisition of Bioniche Pharma and Agila Specialties, two of the world’s most preeminent makers of injectables products. Most recently, Malik played a pivotal role to acquire and close on the acquisition of Abbott’s Established Products business in non-U.S. developed markets, including Europe, Australia, Japan and Canada.  Malik also played a pivotal role in the acquisitions and integrations of Renaissance and Meda which further diversified Mylan’s commercial and operations platform in dermatology and OTC.

    Malik has approximately 30 years of experience in the global pharmaceutical industry. Prior to joining Matrix in 2005, Malik was head of Global Development and Regulatory at Sandoz. He started in R&D at Ranbaxy Laboratories, rising to head of Generics R&D. Malik earned his master's degree in pharmaceutical technology from Punjab University, India, and has more than 60 process patents to his credit.

  • Anthony Mauro

    Chief Commercial Officer

    Mylan

    Anthony (Tony) Mauro is Mylan’s Chief Commercial Officer overseeing all of its commercial businesses around the world. 

    Mauro has been with Mylan for more than 20 years. He has served the company in several capacities of increasing responsibility. Most recently, he served as president of North America, successfully leading the company’s largest commercial business. Prior to that role, Mauro served as president of Mylan Pharmaceuticals Inc., the company's flagship generics division in the U.S.; chief operating officer of Mylan Pharmaceuticals ULC in Canada; vice president of North America Strategic Development; and vice president of North America Sales. 

    In 2012 and 2013, Mauro served as chairman of the board of directors for the U.S. Generic Pharmaceutical Association (GPhA), which represents the world's leading generic drug manufacturers and suppliers. Prior to that he served two consecutive terms as vice chairman of the board for GPhA.

    Mauro is a member of the visiting committee at West Virginia University's Graduate School of Business and Economics. Mauro earned a bachelor's degree in business administration, with a specialization in finance, and a master's degree in business administration from West Virginia University.

  • Ken Parks

    Chief Financial Officer

    Mylan

    Ken Parks is Mylan’s chief financial officer and is responsible for all of the company’s global finance functions, including accounting and control, financial planning and analysis, investor relations, treasury and tax.

    He also leads Mylan’s Global Integrated Services organization, which centralizes the management of transaction-intensive Finance, Human Relations, IT and other activities to drive scale, efficiency and consistency. In addition, he heads up Global Data and Strategic Analytics, which provides actionable insights to the company’s leaders as well as analytics solutions to the broader business.

    Parks joined Mylan in June 2016 from WESCO International, a leading provider of electrical, industrial and communication products, where he led all aspects of the finance function.

    Prior to WESCO, Parks spent the majority of his career at United Technologies Corporation (UTC) in a variety of U.S. and international finance roles. He most recently served as the company’s vice president, Finance, for its $7 billion UTC Fire & Security division. Prior to that, he led UTC’s Investor Relations function.

    In addition, Parks also held several roles at UTC's $10 billion Carrier Corporation division, including director, Financial Planning and Analysis (FP&A), and vice president of Operations Finance. He spent four years in Paris as Controller and then as director, FP&A, for Carrier's European, Middle East and Africa operations. Parks spent his early years at UTC in auditing, financial reporting and controllership.

    He began his career at the accounting firm Coopers & Lybrand, where he became a certified public accountant.

    Parks earned a Bachelor of Science degree in accounting from University of Tulsa.
  • Daniel M. Gallagher

    Chief Legal Officer

    Mylan

    Dan Gallagher has served as chief legal officer since April 2017. Gallagher previously served as president of Patomak Global Partners, a consulting firm providing strategic advice, compliance consulting, and litigation and regulatory enforcement services, from January 2016 to March 2017. As president, Gallagher was responsible for originating and managing client matters and assisting the chief executive officer in overseeing operations of the firm. 

    From November 2011 to October 2015, Gallagher served as a commissioner of the U.S. Securities and Exchange Commission (SEC). During his tenure at the SEC, Gallagher focused on initiatives aimed at strengthening the U.S. capital markets and encouraging capital formation, among others. Before being appointed commissioner, he served on the staff of the SEC in several capacities, including as counsel to both SEC Commissioner Paul Atkins and Chairman Christopher Cox, working on matters involving the Division of Enforcement and the Division of Trading and Markets. Gallagher served as deputy director and co-acting director of the Division of Trading and Markets from 2008 to 2010. 

    In addition to his tenure in public service, he spent a number of years in the private sector. Following law school, he joined the Washington, D.C., law firm Wilmer Cutler & Pickering. He later returned to Wilmer (now WilmerHale) as a partner following his staff service at the SEC. Gallagher also served as senior vice president and general counsel of Fiserv Securities, Inc., where he was responsible for managing all of the firm’s legal and regulatory matters. Gallagher serves as non-executive director of both the Irish Stock Exchange and Symbiont.io and is on the advisory board of the Drexel LeBow Center for Corporate Governance.